Nektar Therapeutics (LTS:0UNL)
$ 1.0204 -0.01 (-0.97%) Market Cap: 188.15 Mil Enterprise Value: 51.91 Mil PE Ratio: 0 PB Ratio: 3.85 GF Score: 54/100

Q1 2019 Nektar Therapeutics Earnings Call Transcript

May 08, 2019 / 09:00PM GMT
Release Date Price: $32.02
Operator

Good day, ladies and gentlemen, and welcome to the Nektar Therapeutics First Quarter 2019 Financial Results Conference Call. (Operator Instructions) As a reminder, this conference call may be recorded.

I would now like to introduce your host for today's conference, Ms. Jennifer Ruddock, Head of Investor Relations. Ma'am, you may begin.

Jennifer Ruddock
Nektar Therapeutics - SVP of IR & Corporate Affairs

Thank you, Crystal. Good afternoon, everyone, and thank you for joining us today. With us are Howard Robin, our President and CEO; Gil Labrucherie, our Chief Financial Officer; Dr. Stephen Doberstein, our Head of R&D; Dr. Jonathan Zalevsky, our Chief Scientific Officer; and Dr. Mary Tagliaferri, our Chief Medical officer.

On today's call, we expect to make forward-looking statements regarding our business, including the timing of future clinical trials and clinical trial results, clinical development plans, including the plans to start future clinical trials; the therapeutic potential of certain drugs and drug candidates as well as

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot